Targeted therapies are now used to treat a wide range of malignancies, and some offer unprecedented clinical benefits. However, as experience with these therapies has increased, we have become cognizant of their limitations. Despite their capacity to induce dramatic remissions, most cancers ultimately develop resistance to these treatments, limiting their clinical benefit. You'll discuss the latest biological insights into the mechanisms of resistance to targeted therapies and the clinical strategies being employed to overcome it.
Objectives